On top of noninferior efficacy, the trial showed patients had less bleeding with 2.5 mg vs 5.0 mg twice daily over 12 months.

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

近年来，心血管疾病的研究不断取得突破性进展，为患者带来了新的希望。在刚刚落幕的ACC.25会议上，三项重磅研究的公布再次引发了广泛关注。这些研究不仅揭示了女性非阻塞性冠心病治疗的新方向，还为外周动脉疾病（PAD）合并2型糖尿病患者提供了全新的治疗选择，同时在癌症患者静脉血栓栓塞（VTE）的治疗中也取得了重要进展。让我们一起来深入了解这些研究的核心内容及其对临床实践的深远影响。

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

In patients with active cancer and venous thromboembolism, whether extended treatment with a reduced dose of an oral anticoagulant is effective in preventing recurrent thromboembolic events and ...

These findings from the API-CAT trial were presented at the American College of Cardiology’s Annual Scientific Session (ACC.25). VTEs are a common complication of cancer and the second leading ...